Searched for
ANTIBODY DRUG CONJUGATE
Cohance Lifesciences to invest USD 18 mn in NJ Bio, Aruka BioCohance Lifesciences announced an eighteen million dollar investment to strengthen its antibody-drug conjugate strategy. This includes thir...- Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 targetJefferies has initiated coverage on Anthem Biosciences with a Buy rating and Rs 1,050 target, implying around 20% upside. The brokerage is ...
- Forget Nvidia chips, China's next big race is being slowed down by an unlikely rival: monkeysLab primate prices in China have surged over 1,000% in eight years, with a single cynomolgus macaque now costing around Rs 22 lakh. The sho...
- Piramal Pharma to focus on policy, not Trump tariff tweets: Nandini PiramalPiramal Pharma will focus on policy actions amid tariff concerns. Its global manufacturing network offers a significant advantage. The comp...
- Laurus Labs shares rally over 4% as Q1FY27 profit jumps 126% on strong CDMO growthLaurus Labs reported a strong June-quarter performance, with net profit more than doubling and revenue rising 29% year-on-year, driven by r...
- Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas TambeBiocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...
- AstraZeneca, Gilead vie for edge in race to treat tough breast cancerNew data from Europe's biggest oncology meeting reveals a high-stakes race for patients with a tough breast cancer. Astra and Daiichi's Dat...
- AstraZeneca gets regulator's nod to market cancer drug in IndiaAstraZeneca Pharma has secured approval from India's drug regulator for its cancer treatment Trastuzumab Deruxtecan. This drug is now appro...
- Glenmark inks pact with Hengrui Pharma for cancer therapy Trastuzumab RezetecanGlenmark Pharmaceuticals has partnered with Hengrui Pharma, securing exclusive rights to develop and commercialize Trastuzumab Rezetecan gl...
- Cohance Lifesciences announces $10 million investment in US-based armCohance Lifesciences is investing USD 10 million to expand bioconjugation capabilities at its US subsidiary, NJ Bio, enhancing its ADC solu...
- Piramal Healthcare targets $2 bn revenue by FY30, to focus on organic expansion: Chairperson Nandini PiramalPiramal Healthcare prioritizes organic growth for the next 4-5 years. The company will explore licensing and product acquisitions in comple...
- AstraZeneca, Daiichi Drug gets broad tumor approval in USEnhertu, a collaboration between AstraZeneca and Daiichi Sankyo, gains FDA approval for treating HER2-positive solid tumors spread througho...
- AstraZeneca bets on licencing deals, public-private partnerships for India growthBritish-Swedish drugmaker AstraZeneca is set to launch 15 new products in India from 2023 to 2025, focusing on oncology, cardiovascular, re...
- SPARC enters licensing pact with Biomodifying for licensing of novel drug targets against cancer“This is an important milestone for SPARC. The licensing of antibodies from Biomodifying will assist us in our endeavour to transition SPAR...
- Cadila Healthcare Q1 results: Net profit rises 29% to Rs 587 crConsolidated total revenue from operations stood at Rs 4,025.4 crore for the quarter under consideration against Rs 3,514.6 crore for the s...
- Zydus Cadila launches breast cancer treatment drug Ujvira"In a step that can significantly reduce treatment cost by almost 80 per cent, the drug is being offered at Rs 32,495 for a 100 mg vial. Th...
- Piramal Healthcare UK Ltd invests £2.0 million in ScotlandThe new facility is expected to create up to 20 new high-skill job roles, backed by £200,000 Regional Selective Assistance funding.
- Piramal Healthcare signs pact with Japan's Fujifilm DiosynthMumbai-based Piramal Healthcare has teamed up with Japan's Fujifilm Diosynth for a contract manufacturing deal that would look to develop a...
- Piramal, Fujifilm Diosynth tie up for biopharmaceuticalsPiramal Enterprises today said its healthcare vertical has tied up with Fujifilm Diosynth Biotechnologies for co-operation in biopharmaceut...
- Biocon to partner US-based firm for developing cancer drugBiotech major Biocon Ltd on Thursday said it will enter into a partnership with a US-based biotechnology company, Iatrica, to develop drug ...
Load More
